Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells
Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells
批准号:
8239386
负责人:
David J Beebe
金额:
$28.11万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-21 至 2017-04-30
关键词:
AddressAdvanced DevelopmentAntineoplastic AgentsAreaBiologicalBiological AssayBiological MarkersBiologyBiomedical EngineeringBiopsy SpecimenBloodBone MarrowBone Marrow CellsBortezomibCancer BiologyCancer PatientCell CountCell Culture TechniquesCell DeathCellsCessation of lifeClassificationCoculture TechniquesDevelopmentDevicesDrug Delivery SystemsDrug IndustryDrug resistanceFutureGenerationsGenesGenomicsHumanKnowledgeLaboratoriesLifeMalignant NeoplasmsManualsMeasuresMediatingMedicineMethodologyMethodsMicrofluidicsMultiple MyelomaNF-kappa BPathologyPathway interactionsPatient CarePatientsPharmaceutical PreparationsPharmacologic SubstanceProteasome InhibitorProteomicsPumpRegulationResearchResearch InfrastructureResistanceRoleSample SizeSamplingSideSignal TransductionSolidSourceSpecimenStromal CellsSystemTechniquesTechnologyTranslational Researchanticancer researchbasecancer cellcancer typecell typedesignflexibilityhigh throughput analysishigh throughput technologyimprovedinnovationinsightkillingsnovelprototyperesponsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In contrast to highly sensitive genomic and proteomic methods that primarily evaluate the state of cancer specimens, functional analyses of primary patient samples to assess their biological responses to various experimental conditions are difficult because of the often limited number of live primary cells that can be obtained from patient biopsy samples. Thus, overcoming this technical barrier has the potential to transform our ability to significantly increase translational cancer research approaches. By combining expertise in, cancer cell signaling, bioengineering, and primary patient care, the Miyamoto-Beebe-Callander team proposes to improve our ability to functionally analyze NF-kB signal transduction responses in primary patient multiple myeloma (MM) samples. Specifically, we propose to develop innovative microchannel culture devices and implement functional studies to investigate a dogma-challenging NF-kB-survival pathway in MM. We have already developed prototype culture devices that increase our ability to analyze primary MM cells. These microculture systems also provide the flexibility to study components of the tumor microenvironment, such as tumor-supporting bone marrow stromal cells (BMSCs). Under Aim 1 we will dissect drug resistance-inducing NF-kB signaling mechanisms in primary MM cells using the first generation microscale cell culture chambers (MCCCs). We also aim to reveal patient individualized information by co- culturing MM cells and BMSCs derived from the same patients, a paradigm shift from the conventional experimental setup where patient sources of MM and BMSCs are randomly mixed. Under Aim 2 we will further improve functional micro-scale assays with additional functionalities and with even smaller cell numbers per condition, thus greatly expanding the scope of translational research in MM. The micro-culture technology proposed has the potential to rapidly change the methods used for investigating signal transduction studies, including NF-kB, in MM and other blood and possibly solid cancer types.
PUBLIC HEALTH RELEVANCE: Many anticancer agents are used to kill cancer cells, but unfortunately cancer cells turn on survival mechanisms to counter the death effect. One of these mechanisms is the activation of the transcription factor NF-kB that rapidly turns on synthesis of survival genes. The proposed research will reveal an important mechanism of NF-kB pathway in patient multiple myeloma cells by developing innovative microculture methods that enable the systematic and high throughput analysis of precious patient cancer samples. This study is expected to uncover an important survival mechanism that may serve as a future drug target to improve treatment of this currently incurable cancer type.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a human intestinal microphysiological system for the study of immune responses to protozoan parasites
-
批准号:10733303
-
项目类别:
-
资助金额:$76.91万
-
财政年份:2023
-
负责人:David J Beebe
-
依托单位:
Under-oil open microfluidic system (UOMS) for studying systemic fungal infection
-
批准号:10333399
-
项目类别:
-
资助金额:$76.42万
-
财政年份:2021
-
负责人:David J Beebe
-
依托单位:
Under-oil open microfluidic system (UOMS) for studying systemic fungal infection
-
批准号:10552700
-
项目类别:
-
资助金额:$77.08万
-
财政年份:2021
-
负责人:David J Beebe
-
依托单位:
Under-oil open microfluidic system (UOMS) for studying systemic fungal infection
-
批准号:10209529
-
项目类别:
-
资助金额:$72.84万
-
财政年份:2021
-
负责人:David J Beebe
-
依托单位:
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics
-
批准号:9916997
-
项目类别:
-
资助金额:$61.09万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics
-
批准号:10331769
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics
-
批准号:10686449
-
项目类别:
-
资助金额:$77.75万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics
-
批准号:10263962
-
项目类别:
-
资助金额:$85.43万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics
-
批准号:10094211
-
项目类别:
-
资助金额:$63.43万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
A multiplexed micro scale assay for real time analysis of pediatric immune cell function
-
批准号:10380807
-
项目类别:
-
资助金额:$36.04万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
A multiplexed micro scale assay for real time analysis of pediatric immune cell function
-
批准号:10132990
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics
-
批准号:10552039
-
项目类别:
-
资助金额:$62.16万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics
-
批准号:10707411
-
项目类别:
-
资助金额:$77.75万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics
-
批准号:10038030
-
项目类别:
-
资助金额:$77.54万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
A multiplexed micro scale assay for real time analysis of pediatric immune cell function
-
批准号:10599320
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2020
-
负责人:David J Beebe
-
依托单位:
Microscale models of inflammation and its resolution
-
批准号:10372948
-
项目类别:
-
资助金额:$75.23万
-
财政年份:2018
-
负责人:David J Beebe
-
依托单位:
Microscale models of inflammation and its resolution
-
批准号:9904469
-
项目类别:
-
资助金额:$75.23万
-
财政年份:2018
-
负责人:David J Beebe
-
依托单位:
Project 2: Predicting Treatment Responses Using Single Cell RNA Sequencing and Bioengineered Patient-derived Organotypic Models of HNC
-
批准号:10495294
-
项目类别:
-
资助金额:$37.09万
-
财政年份:2016
-
负责人:David J Beebe
-
依托单位:
Project 2: Predicting Treatment Responses Using Single Cell RNA Sequencing and Bioengineered Patient-derived Organotypic Models of HNC
-
批准号:10673977
-
项目类别:
-
资助金额:$36.81万
-
财政年份:2016
-
负责人:David J Beebe
-
依托单位:
An automated high-throughput tissue model for screening metastatic effectors
-
批准号:8817450
-
项目类别:
-
资助金额:$61.05万
-
财政年份:2015
-
负责人:David J Beebe
-
依托单位:
海外基金